Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma

• Maura C. Gillis, BA,
• Vanessa R. Weir, BA,
• Cecilia Lezcano, MD,
• Gopa Iyer, MD,
• Allison Gordon, MD

Affiliations

Maura C. Gillis, BA

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Vanessa R. Weir, BA

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Cecilia Lezcano, MD

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Gopa Iyer, MD

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York

Allison Gordon, MD

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Correspondence to: Allison Gordon, MD, Dermatology Service, Department of Medicine, David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York, NY 10021.